CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: a multicenter study

被引：0

作者：

Ufuk Demirci

Hakkı Onur Kırkızlar

Elif G. Ümit

Vildan Gürsoy

İbrahim Ethem Pınar

Fahir Özkalemkaş

Zeynep Tuğba Güven

Leylagül Kaynar

Fatma Keklik Karadağ

Güray Saydam

Ömer Ekinci

Mustafa Merter

Merih Reis Aras

Murat Albayrak

Sedanur Karaman Gülsaran

Volkan Baş

Berrin Balık Aydın

Hüseyin Saffet Beköz

Ferda Can

İmdat Dilek

Özgür Mehtap

Erman Öztürk

Bengü Çöbanoğlu Şimşek

Murat Yıldırım

Meltem Aylı

Ünal Ataş

Ozan Salim

Mesut Ayer

Elif Birtaş Ateşoğlu

Olga Meltem Akay

Meltem Kurt Yüksel

Semra Paydaş

Selçuk Korkmaz

Fulya Öz Puyan

Ahmet Muzaffer Demir

机构：

[1] Trakya University,Medical Faculty, Department of Hematology

[2] Uludağ University,Medical Faculty, Department of Hematology

[3] Erciyes University,Medical Faculty, Department of Hematology

[4] Ege University,Medical Faculty, Department of Hematology

[5] Medicana International Hospital,Department of Hematology

[6] Fırat University,Medical Faculty, Department of Hematology

[7] Health Sciences University,Dışkapı Yıldırım Beyazıt Training and Research Hospital, Department of Hematology

[8] Medipol University,Medical Faculty, Department of Hematology

[9] Ankara City Hospital,Department of Hematology

[10] Kocaeli University,Medical Faculty, Department of Hematology

[11] Medeniyet University,Medical Faculty, Department of Hematology

[12] Health Sciences University Gülhane Training and Research Hospital,Department of Hematology

[13] Akdeniz University,Medical Faculty, Department of Hematology

[14] Çam Sakura Training and Research Hospital,Department of Hematology

[15] Koç University,Medical Faculty, Department of Hematology

[16] Ankara University,Medical Faculty, Department of Hematology

[17] Çukurova University,Medical Faculty, Department of Hematology

[18] Trakya University,Medical Faculty, Department of Biostatistics and Medical Informatics

[19] Trakya University,Medical Faculty, Department of Pathology

来源：

Journal of Hematopathology | 2022年 / 15卷

关键词：

Diffuse large B-cell lymphoma; CD 5; Double/triple expressor; CNS prophylaxis; c-MYC;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and comprises a heterogeneous group of disease. While classification of B-cell lymphomas has been evolving to include clonality in a specific manner, morphology, and immunohistochemistry remain the backbone. We aimed to evaluate the value of CD5 expression on disease characteristics as well as prognosis in patients with DLBCL. Data of 131 patients with DLBCL with CD5 positivity and as a comparison arm, data of 129 patients with DLBCL without CD5 positivity were evaluated. Mean age was 59 and 55.7% of the patients were male. Overall survival was 29.8 months. Poor prognostic factors including (high-LDH levels, B symptoms, low ECOG score, high R-IPI and NCCN-IPI score) were observed to be significantly related with CD5 positivity. Mean survival in CD5 positive patients were 29.8 months, which is significantly shorter than the general DLBCL survival worldwide. CD5 expression shall be evaluated in all samples of DLBCL patients due to its possible effects on outcomes.

引用

页码：203 / 213

页数：10

共 61 条

[1] Liu Y(2019)Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment Am J Hematol 94 604-616
[2] Barta SK(2015)Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis treatment and follow-up Ann Oncol 2 116-125
[3] Tilly H(2018)Diffuse large B-cell lymphoma Pathology 50 74-87
[4] Silva MG(2019)Clinical significance of BCL2, C-MYC, and BCL6 genetic abnormalities, Epstein-Barr virus infection, CD5 protein expression, germinal center B cell/non-germinal center B-cell subtypes, co-expression of MYC/BCL2 proteins and co-expression of MYC/BCL2/BCL6 proteins in diffuse large B-cell lymphoma: a clinical and pathological correlation study of 120 patients Int J Med Sci 16 556-566
[5] Vitolo U(2004)Confirmation of the molecular classification of diffuse large B-cell lymphoma by immuno- histochemistry using a tissue microarray Blood 103 275-282
[6] Li S(2005)Cytogenetic features of de novo CD5- positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival Genes Chromosomes Cancer 42 149-157
[7] Young KH(2019)Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma Hematology 24 446-454
[8] Medeiros J(2013)Recent advances in de novo CD5+ diffuse large B cell lyphoma Am J Hematol 88 798-802
[9] Ting CY(2019)Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: high incidence of BCL2 and MYC double-expressors PLoS One 14 e0224247-21
[10] Chang KM(2002)De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients Blood 99 815-33

← 1 2 3 4 5 6 7 →